Combined effects of Lenvatinib and zinc oxide nanoparticles by promoting apoptosis and anti-proliferative activity in mice bearing Ehrlich solid tumors
Source abstract
Abstract
Abstract Objective The objective of this study is to evaluate the anticancer activity of lenvatinib and zinc oxide nanoparticles (ZnO-NPs) separately and in combination and whether ZnO-NPs can reduce resistance to lenvatinib treatment. Methods TEM, SEM, Zeta, DLS, UV, FTIR, and XRD performed to characterize ZnO-NPs. Fifty mature female Swiss albino mice bearing solid Ehrlich carcinoma (SEC) were randomly divided into five equal groups: Negative control, SEC, Lenvatinib, ZnO-NPs, and Lenvatinib + ZnO-NPs. All treatments were administered for 4 weeks. Results A decrease in tumor volume (458.6 mm 3 ) and an increase in tumor growth inhibition (67.6%) were observed in the combination groups. In the combination group, there was a decrease in serum ALT and AST levels. Besides, there was a significant increase in reactive oxygen species (ROS), malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-α) accompanied by depletion in superoxide dismutase (SOD) and catalase, in tumor tissues. Notably, the anti-apoptotic marker Bcl-2 significantly decreased, while caspase-3 and caspase-9 levels in blood samples and caspase-3 expression in tumor tissues increased significantly. Cell cycle research revealed a G2/M phase arrest in tumor samples. Additionally, Cyclin D1 expression (0.63) was significantly reduced by western blotting, and immunohistochemical staining showed lower Ki-67 levels (46.6%). Elevation of apoptosis and necrosis was confirmed by histopathological analysis of tumor sections. Also, histopathological examination of major organs (liver, kidney, heart, and spleen) showed no discernible damage. Conclusion According to these results, zinc oxide nanoparticles may increase lenvatinib's anticancer effectiveness by promoting apoptosis and inhibiting proliferation. Future clinical research may employ the combination because it seems to be both safe and effective.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Cancer, Lipids, and Metabolism · Chemotherapy-induced organ toxicity mitigation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (70)
Show source-provided references
1. Liu B, et al. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):175. https://doi.org/10.1038/s41392-024-01856-7.10.1038/s41392-024-01856-7 ↗
2. Ribeiro Franco PI, et al. Tumor microenvironment components: allies of cancer progression. Pathol Res Pract. 2020;216(1):152729. https://doi.org/10.1016/j.prp.2019.152729.10.1016/j.prp.2019.152729 ↗
3. Jiang X, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020;39(1):204. https://doi.org/10.1186/s13046-020-01709-5.10.1186/s13046-020-01709-5 ↗
4. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131. https://doi.org/10.1186/s13045-022-01351-y.10.1186/s13045-022-01351-y ↗
5. Zafar A, et al. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol. 2025;16(1):607. https://doi.org/10.1007/s12672-025-02198-8.10.1007/s12672-025-02198-8 ↗
6. Debela DT, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034370. https://doi.org/10.1177/20503121211034366.10.1177/20503121211034366 ↗
7. Shahid N, et al. Inhibition of purine nucleoside and nucleobase transporters by tyrosine kinase inhibitors. PLoS ONE. 2026;21(5):e0348426. https://doi.org/10.1371/journal.pone.0348426.10.1371/journal.pone.0348426 ↗
8. Yamamoto Y, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6(1):18.10.1186/2045-824X-6-18 ↗
9. Zhou J, et al. Synthesis of lenvatinib-loaded upconversion@ polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer. RSC Adv. 2023;13(38):26925–32. https://doi.org/10.1039/d3ra02121a.10.1039/d3ra02121a ↗
10. Wei G, et al. Lenvatinib-zinc phthalocyanine conjugates as potential agents for enhancing synergistic therapy of multidrug-resistant cancer by glutathione depletion. Eur J Med Chem. 2019;169:53–64. https://doi.org/10.1016/j.ejmech.2019.02.065.10.1016/j.ejmech.2019.02.065 ↗
11. Revilla G, et al. Lenvatinib-loaded poly(lactic-co-glycolic acid) nanoparticles with epidermal growth factor receptor antibody conjugation as a preclinical approach to therapeutically improve thyroid cancer with aggressive behavior. Biomolecules. 2023. https://doi.org/10.3390/biom13111647.10.3390/biom13111647 ↗
12. Ali KH, et al. Zinc Oxide Nanoparticles Induces Apoptosis in Human Breast Cancer Cells via Caspase-8 and P53 Pathway. Nano Biomedicine and Engineering. 2019;11(1):35–43. https://doi.org/10.5101/nbe.v11i1.p35-43.10.5101/nbe.v11i1.p35-43 ↗
13. Sulaiman A, Wang LJO. Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors. Oncotarget. 2017;8(68):113269. https://doi.org/10.18632/oncotarget.22916.10.18632/oncotarget.22916 ↗
14. Tseriotis VS, et al. ZnO-based nanoparticles for targeted cancer chemotherapy and the role of tumor microenvironment: a systematic review. Int J Mol Sci. 2025. https://doi.org/10.3390/ijms26178417.10.3390/ijms26178417 ↗
15. Lebaka VR, et al. Zinc oxide nanoparticles in modern science and technology: multifunctional roles in healthcare, environmental remediation, and industry. Nanomaterials. 2025. https://doi.org/10.3390/nano15100754.10.3390/nano15100754 ↗
16. Yan M, Majd MH. Evaluation of induced apoptosis by biosynthesized zinc oxide nanoparticles in MCF-7 breast cancer cells using Bak1 and Bclx expression. In: Doklady Biochemistry and Biophysics. Springer; 2021.
17. Dawood L, et al. Anti-proliferative effect of ZnO NPs against the growth of Ehrlich solid carcinoma. Journal of Medical and Life Science. 2019;1(4):110–22. https://doi.org/10.21608/jmals.2019.180380.10.21608/jmals.2019.180380 ↗
18. Jayalakshmi CS, Haider M, Sanpui P. Tyrosine kinase inhibitor-loaded zein nanoparticles with enhanced drug delivery and anticancer efficacy. Int J Biol Macromol. 2025;314:143898. https://doi.org/10.1016/j.ijbiomac.2025.143898.10.1016/j.ijbiomac.2025.143898 ↗
19. Ozaslan M, et al. Ehrlich ascites carcinoma. Afr J Biotechnol. 2011;10(13):2375–8. https://doi.org/10.5897/AJBx10.017.10.5897/AJBx10.017 ↗
20. Ghorbani HR, et al. Synthesis of ZnO nanoparticles by precipitation method. Orient J Chem. 2015;31(2):1219–21. https://doi.org/10.13005/ojc/310281.10.13005/ojc/310281 ↗
21. El-Haddad MN. Chitosan as a green inhibitor for copper corrosion in acidic medium. Int J Biol Macromol. 2013;55:142–9. https://doi.org/10.1016/j.ijbiomac.2012.12.044.10.1016/j.ijbiomac.2012.12.044 ↗
22. Osman AE-MM, et al. Hyperthermic potentiation of cisplatin cytotoxicity on solid Ehrlich carcinoma. Tumori J. 1993;79(4):268–72. https://doi.org/10.1177/030089169307900408.10.1177/030089169307900408 ↗
23. Yoshida T, et al. Efficacy of nanofiber sheets incorporating lenvatinib in a hepatocellular carcinoma xenograft model. Nanomaterials (Basel). 2022. https://doi.org/10.3390/nano12081364.10.3390/nano12081364 ↗
24. Nabil A, et al. Zinc oxide nanoparticle synergizes sorafenib anticancer efficacy with minimizing its cytotoxicity. Oxid Med Cell Longev. 2020. https://doi.org/10.1155/2020/1362104.10.1155/2020/1362104 ↗
25. Haggag YA, et al. Polymeric nano-encapsulation of 5-fluorouracil enhances anti-cancer activity and ameliorates side effects in solid Ehrlich carcinoma-bearing mice. Biomed Pharmacother. 2018;105:215–24. https://doi.org/10.1016/j.biopha.2018.05.124.10.1016/j.biopha.2018.05.124 ↗
26. Lu Y, et al. A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway. J Nanobiotechnol. 2021;19(1):115. https://doi.org/10.1186/s12951-021-00799-3.10.1186/s12951-021-00799-3 ↗
27. Othman AI, et al. Polyphenon-E encapsulated into chitosan nanoparticles inhibited proliferation and growth of Ehrlich solid tumor in mice. Egypt J Basic Appl Sci. 2018;5(1):110–20. https://doi.org/10.1016/j.ejbas.2017.10.008.10.1016/j.ejbas.2017.10.008 ↗
28. Gray JW, Coffino P. Cell cycle analysis by flow cytometry. Methods Enzymol. 1979;58:233–48. https://doi.org/10.1016/s0076-6879(79)58140-3.10.1016/s0076-6879(79)58140-3 ↗
29. Sharma N, et al. Plumbago zeylanica L. exhibited potent anticancer activity in Ehrlich ascites carcinoma bearing Swiss albino mice. J King Saud Univ. 2023;35(9):102932. https://doi.org/10.1016/j.jksus.2023.102932.10.1016/j.jksus.2023.102932 ↗
30. Mansour SM, Ibrahim RYM. Zofenopril antitumor activity in mice bearing Ehrlich solid carcinoma: modulation of PI3K/AKT signaling pathway. Braz J Pharm Sci. 2022;58:e19922. https://doi.org/10.1590/s2175-97902022e19922.10.1590/s2175-97902022e19922 ↗
31. Alshehri AF, Khodier AE, Al-Gayyar MM. Antitumor activity of Ligustilide against Ehrlich solid carcinoma in rats via inhibition of proliferation and activation of autophagy. Cureus. 2023;15(6):e40499. https://doi.org/10.7759/cureus.40499.10.7759/cureus.40499 ↗
32. Abu-Bader SH. Using statistical methods in social science research: with a complete SPSS guide. USA: Oxford University Press; 2021.
33. Levine KE, et al. Characterization of zinc carbonate basic as a source of zinc in a rodent study investigating the effects of dietary deficiency or excess. Anal Lett. 2017;50(15):2447–64. https://doi.org/10.1080/00032719.2017.1293073.10.1080/00032719.2017.1293073 ↗
34. Kołodziejczak-Radzimska A, Jesionowski TJM. Zinc oxide—from synthesis to application: a review. Materials (Basel). 2014;7(4):2833–81. https://doi.org/10.3390/ma7042833.10.3390/ma7042833 ↗
35. Zhou J, et al. Size-controlled synthesis of ZnO nanoparticles and their photoluminescence properties. Luminescence. 2007;122:195–7. https://doi.org/10.1016/j.jlumin.2006.01.089.10.1016/j.jlumin.2006.01.089 ↗
36. Khoshhesab ZM, et al. Preparation of ZnO nanostructures by chemical precipitation method. Synth React Inorg Met-Org Nano-Met Chem. 2011;41(7):814–9. https://doi.org/10.1080/15533174.2011.591308.10.1080/15533174.2011.591308 ↗
37. JCPDS, P.D.F.J.I.C., International Centre for Diffraction Data, Newtown Square, Pa, USA, Alphabetical index. 1977.
38. Sreelakshmi, T., A.R. Prasad, and A.J.J.o.t.I.C.S. Joseph, Synthesis, characterization, and effective removal of dye pollutants from water bodies using a new ZnO nanocomposite. Journal of the Indian Chemical Society, 2024. 101(8): p. 101183. https://doi.org/10.1016/j.jics.2024.101183.10.1016/j.jics.2024.101183 ↗
39. Rajendran, S.P. and K.J.J.o.N. Sengodan, Synthesis and characterization of zinc oxide and iron oxide nanoparticles using Sesbania grandiflora leaf extract as reducing agent. J Nanosci 2017. 2017(1): p. 8348507. https://doi.org/10.1155/2017/8348507.10.1155/2017/8348507 ↗
40. Validžić IL, et al. Structural and optical characterization of hemimorphite with flower-like morphology synthesized by a novel low-temperature method. Mater Lett. 2012;85:138–41.10.1016/j.matlet.2012.06.111 ↗
41. Saleh N, et al. Review on Ehrlich ascites carcinoma in mice and cancer treatment with special reference to the potential protective and therapeutic effects of hesperidin versus cisplatin. J Curr Vet Res. 2022;4(1):47–57. https://doi.org/10.21608/jcvr.2022.240866.10.21608/jcvr.2022.240866 ↗
42. Valdiglesias V, et al. Neuronal cytotoxicity and genotoxicity induced by zinc oxide nanoparticles. Environ Int. 2013;55:92–100. https://doi.org/10.1016/j.envint.2013.02.013.10.1016/j.envint.2013.02.013 ↗
43. Matsuki M, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641–53. https://doi.org/10.1002/cam4.1517.10.1002/cam4.1517 ↗
44. Wang X, et al. Combination of vitamin C and lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro. PeerJ. 2023;11:e14610. https://doi.org/10.7717/peerj.14610.10.7717/peerj.14610 ↗
45. Sun, D., et al., Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Cancer Metabolism, 2022. Volume 12 - 2022. https://doi.org/10.3389/fonc.2022.944537.10.3389/fonc.2022.944537 ↗
46. Eissa SM, et al. Apoptosis induction and tumor growth suppression by hydroxyapatite nanoparticles–cisplatin combined treatment in Ehrlich solid carcinoma-bearing mice. Beni-Suef Univ J Basic Appl Sci. 2025;14(1):5. https://doi.org/10.1186/s43088-025-00595-0.10.1186/s43088-025-00595-0 ↗
47. Hoshi T, et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR–MAPK cascades. Biochem Biophys Res Commun. 2019;513(1):1–7. https://doi.org/10.1016/j.bbrc.2019.02.015.10.1016/j.bbrc.2019.02.015 ↗
48. Anjum S, et al. Recent advances in zinc oxide nanoparticles (ZnO NPs) for cancer diagnosis, target drug delivery, and treatment. Cancers (Basel). 2021;13(18):4570. https://doi.org/10.3390/cancers13184570.10.3390/cancers13184570 ↗
49. Wang G, et al. Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress. Exp Ther Med. 2018;16(4):3325–32. https://doi.org/10.3892/etm.2018.6652.10.3892/etm.2018.6652 ↗
50. El-Shorbagy HM, et al. Apoptosis and oxidative stress as relevant mechanisms of antitumor activity and genotoxicity of ZnO-NPs alone and in combination with N-acetyl cysteine in tumor-bearing mice. Int J Nanomedicine. 2019;14:3911–28. https://doi.org/10.2147/ijn.S204757.10.2147/ijn.S204757 ↗
51. Hamad, A.M., R.H. Elgebaly, and F.M.J.W.A.S.J. Ali, Subcutaneous Ehrlich Tumor Growth Retardation Using Extremely Low Frequency Magnetic Pulses (ELF MPs). World Applied Sciences Journal 2016. 34(2): p. 229–236. https://doi.org/10.5829/idosi.wasj.2016.34.2.15653.10.5829/idosi.wasj.2016.34.2.15653 ↗
52. Medhat D, et al. Effect of Au-dextran NPs as anti-tumor agent against EAC and solid tumor in mice by biochemical evaluations and histopathological investigations. Biomed Pharmacother. 2017;91:1006–16. https://doi.org/10.1016/j.biopha.2017.05.043.10.1016/j.biopha.2017.05.043 ↗
53. Silva LS, et al. Garcinia brasiliensis leaves extracts inhibit the development of ascitic and solid Ehrlich tumors. Pharmaceuticals (Basel). 2025;18(1):24. https://doi.org/10.3390/ph18010024.10.3390/ph18010024 ↗
54. Radwan AM, et al. Fenugreek-mediated synthesis of zinc oxide nanoparticles and evaluation of its in vitro and in vivo antitumor potency. Biomed Res Ther. 2021;8(8):4483–96. https://doi.org/10.15419/bmrat.v8i8.687.10.15419/bmrat.v8i8.687 ↗
55. Kapur AK, Sharma S, Patankar MS. Targeting tumors through enhancers of oxidative stress. In: Chakraborti S, editor. Handbook of oxidative stress in cancer: therapeutic aspects. Singapore: Springer Nature Singapore; 2022. p. 3563–87.10.1007/978-981-16-5422-0_164 ↗
56. Li Z, et al. Zinc oxide nanoparticles induce human multiple myeloma cell death via reactive oxygen species and Cyt-C/Apaf-1/Caspase-9/Caspase-3 signaling pathway in vitro. Biomed Pharmacother. 2020;122:109712. https://doi.org/10.1016/j.biopha.2019.109712.10.1016/j.biopha.2019.109712 ↗
57. Motafeghi F, Mortazavi P, Shokrzadeh M. Anticancer activity of zinc oxide nanoparticles on prostate and colon cancer cell line. Toxicol Res. 2024. https://doi.org/10.1093/toxres/tfad127.10.1093/toxres/tfad127 ↗
58. Wang W, et al. Deep learning predicts and in vitro experiments validates the synergistic anti-liver cancer effect of vincristine and lenvatinib: mechanism involving apoptosis induction via the TNF-α/Caspase-8 pathway. Biochem Biophys Res Commun. 2026;805:153380. https://doi.org/10.1016/j.bbrc.2026.153380.10.1016/j.bbrc.2026.153380 ↗
59. Zhou J, et al. Mechanism of RCD and the role of different death signaling pathways in cancer. Biomedicines. 2025;13(8):1880. https://doi.org/10.3390/biomedicines13081880.10.3390/biomedicines13081880 ↗
60. Deniz GY, Altun S. Evaluation of nickel-induced brain injuries in rats via oxidative stress and apoptosis: attenuating effects of hyperoside. Turkish Journal of Zoology. 2020;44(2):104–13. https://doi.org/10.3906/zoo-1911-1.10.3906/zoo-1911-1 ↗
61. Li J, et al. A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma. Mol Med Rep. 2017;16(5):7105–11. https://doi.org/10.3892/mmr.2017.7456.10.3892/mmr.2017.7456 ↗
62. Enomoto K, et al. Synergistic effects of lenvatinib (E7080) and MEK inhibitors against anaplastic thyroid cancer in preclinical models. Cancers (Basel). 2021;13(4):862. https://doi.org/10.3390/cancers13040862.10.3390/cancers13040862 ↗
63. Akhtar MJ, et al. Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int J Nanomedicine. 2012;7:845–57. https://doi.org/10.2147/ijn.S29129.10.2147/ijn.S29129 ↗
64. Lee YS, et al. Anti-cancer effects of HNHA and lenvatinib by the suppression of EMT-mediated drug resistance in cancer stem cells. Neoplasia. 2018;20(2):197–206. https://doi.org/10.1016/j.neo.2017.12.003.10.1016/j.neo.2017.12.003 ↗
65. Tong X, et al. Lenvatinib acts on platelet-derived growth factor receptor β to suppress the malignant behaviors of gastric cancer cells. Oncol Lett. 2024;28(4):483. https://doi.org/10.3892/ol.2024.14616.10.3892/ol.2024.14616 ↗
66. Alipour S, et al. Alantolactone and ZnO nanoparticles induce apoptosis activity of cisplatin in an ovarian cancer cell line (SKOV3). Res Pharm Sci. 2022. https://doi.org/10.4103/1735-5362.343083.10.4103/1735-5362.343083 ↗
67. Nakahara M, et al. Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells. Biomed Rep. 2022;17(4):78. https://doi.org/10.3892/br.2022.1561.10.3892/br.2022.1561 ↗
68. Gu W, Yang C. Zinc oxide nanoparticles mitigate the malignant progression of ovarian cancer by mediating autophagy-dependent ferroptosis. J Cancer Res Clin Oncol. 2024;150(12):513. https://doi.org/10.1007/s00432-024-06029-1.10.1007/s00432-024-06029-1 ↗
69. Revilla G, et al. Lenvatinib-loaded poly(lactic-co-glycolic acid) nanoparticles with epidermal growth factor receptor antibody conjugation as a preclinical approach to therapeutically improve thyroid cancer with aggressive behavior. Biomolecules. 2023;13(11):1647. https://doi.org/10.3390/biom13111647.10.3390/biom13111647 ↗
70. Aly HS, et al. Green synthesis of ZnO nanoparticles using Syzygium aromaticum (clove) extract and its radio-modifying effect in Ehrlich tumor-bearing mice. Egypt J Chem. 2024. https://doi.org/10.21608/ejchem.2024.334797.10810.10.21608/ejchem.2024.334797.10810 ↗